基于结构的设计和新型高强度和选择性KRASG12C抑制剂的合成
Kai Gao1, Liming Bao1, Shiyu Li1
1Forward Pharmaceuticals Co. Ltd., Shenzhen, 518063, Guangdong Province, PR China.
European journal of medicinal chemistry
|November 4, 2025
概括
针对KRAS G12C突变的新型抑制剂在治疗NSCLC和CRC等癌症方面表现有前途. 这些新化合物有效地对抗抗性突变,并表现出强大的抗瘤活性,具有良好的口服生物可用性.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉斯G12C突变是各种固体瘤的关键驱动因素,包括非小细胞肺癌 (NSCLC) 和结直肠腺癌 (CRC).
- 现有的共价KRAS G12C抑制剂显示出临床益处,但由于获得的耐药性突变而面临挑战,例如R68S.
研究的目的:
- 开发新的KRAS G12C抑制剂,克服抵抗机制.
- 设计具有改善药理性质和抗瘤功效的化合物.
主要方法:
- 理性核心架构工程使用6,8-二化素核心.
- 在体外对KRAS G12C和KRAS G12C-R68S变体进行细胞功效测试.
- 在直肠异种移植模型中进行药理动力学分析和体内疗效研究.
主要成果:
- 化合物19和20表现出对KRAS G12C驱动的扩散的亚纳米级功效,并保留了对R68S抗性突变的显著活性.
- 优化的药物动力学特征导致高口服生物利用率和持续的瘤暴露.
- 化合物在直肠外移植中显示出几乎完全的瘤回归,没有可观察到的毒性.
结论:
- 核心支架工程是一个可行的策略,以克服KRAS G12C抑制剂耐药性.
- 化合物19和20代表具有强大的抗癌活性,有利的药物处置和耐药性覆盖的先进,适合转化发展.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K


